Natco‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌ Pharma Interim Dividend: Last Day to Purchase the Stock Before Interim Dividend

Hyderabad, 19 November 2025: With respect to its interim dividend of ₹1.50 per share, Natco Pharma Ltd will be trading ex dividend on 20 November 2025. 19 November 2025 is the last day of purchasing shares that will make investors eligible to receive the ‍‌‍‍‌‍‌‍‍‌dividend.

Why Is Eligibility Closing Today?

With the Indian markets operating on the T+1 settlement cycle, shares bought today will be credited to the investors’ demat accounts on the next working day. The purchase of shares has to reflect in the demat account by 20 November if it has to be counted as a shareholder on-record date before the ex-dividend date. Hence, only those transactions that are completed on or before 19 November will qualify for the interim dividend. Those buying on or after the ex-dividend date will not get the ₹1.50 dividend.

Details of Dividend Distribution

One share means a dividend of ₹1.50; thus, ten shares will give a return of ₹15. Fifty shares will yield ₹75; and one hundred shares will give a ₹150 dividend. The payout method is absolutely identical for all the holders, and it depends solely on how many shares you have before the ex-date.

Ongoing Dividend Track Record of Natco Pharma

This company has been issuing interim dividends regularly for a long time, as it can be seen from the multiple times that the firm has in the past few years declared similar disbursements. Essentially, in August 2025 the enterprise announced an interim dividend of ₹2, and afterwards, in February 2025, a dividend of ₹1.50 was given. The company also gave out dividends in 2024 and 2023. The chronological sequence of these events carries significant relevance because it reflects the company’s commitment to the shareholders and is also indicative of good operating results funded by high cash flow.

Stock Performance

The market is responding well to the announcement; with the share price of Natco Pharma climbing to ₹830.55, up 1.96% as of 10:17 am IST.

Hyderabad-based Natco Pharma Ltd is one of the frontline contributors of India’s pharmaceutical industry through its oncology, niche generics, and specialty formulations segments. Besides, the consistent dividend-paying nature of the company is a strong indication of its financial soundness and good capital management practices ‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌‍‌‍‍‌.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations